JP2020525032A5 - - Google Patents

Download PDF

Info

Publication number
JP2020525032A5
JP2020525032A5 JP2019572485A JP2019572485A JP2020525032A5 JP 2020525032 A5 JP2020525032 A5 JP 2020525032A5 JP 2019572485 A JP2019572485 A JP 2019572485A JP 2019572485 A JP2019572485 A JP 2019572485A JP 2020525032 A5 JP2020525032 A5 JP 2020525032A5
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
immune effector
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019572485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020525032A (ja
Filing date
Publication date
Priority claimed from PCT/CN2017/090343 external-priority patent/WO2019000223A1/en
Application filed filed Critical
Publication of JP2020525032A publication Critical patent/JP2020525032A/ja
Publication of JP2020525032A5 publication Critical patent/JP2020525032A5/ja
Pending legal-status Critical Current

Links

JP2019572485A 2017-06-27 2018-06-27 キメラ抗体免疫エフェクター細胞エンゲージャー及びその使用方法 Pending JP2020525032A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2017/090343 WO2019000223A1 (en) 2017-06-27 2017-06-27 ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
CNPCT/CN2017/090343 2017-06-27
PCT/CN2018/093135 WO2019001474A1 (en) 2017-06-27 2018-06-27 ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF

Publications (2)

Publication Number Publication Date
JP2020525032A JP2020525032A (ja) 2020-08-27
JP2020525032A5 true JP2020525032A5 (enExample) 2021-07-26

Family

ID=64740850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019572485A Pending JP2020525032A (ja) 2017-06-27 2018-06-27 キメラ抗体免疫エフェクター細胞エンゲージャー及びその使用方法

Country Status (6)

Country Link
US (1) US11827713B2 (enExample)
EP (1) EP3645574A4 (enExample)
JP (1) JP2020525032A (enExample)
CN (1) CN110719919A (enExample)
TW (1) TW201906867A (enExample)
WO (2) WO2019000223A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641049B (zh) 2016-06-21 2023-07-07 特尼奥生物股份有限公司 Cd3结合抗体
KR102512934B1 (ko) * 2016-08-10 2023-03-23 레전드 바이오테크 아일랜드 리미티드 Bcma를 표적으로 하는 키메라 항원 수용체 및 이들의 이용 방법
MY200988A (en) 2016-09-14 2024-01-27 Teneobio Inc CD3 Binding Antibodies
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
WO2018237006A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. Anti-bcma heavy chain-only antibodies
IL312322B2 (en) 2017-06-20 2026-05-01 Teneobio Inc Antibodies against BCMA containing only heavy chains
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
AU2019277029C1 (en) 2018-06-01 2024-01-04 Novartis Ag Binding molecules against BCMA and uses thereof
CR20210500A (es) 2019-04-05 2021-11-05 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
CN109942709B (zh) * 2019-04-22 2019-12-27 广州百暨基因科技有限公司 一种抗bcma的单域抗体及其应用
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
JP7665538B2 (ja) 2019-06-14 2025-04-21 テネオバイオ, インコーポレイテッド Cd22及びcd3に結合する多重特異性重鎖抗体
WO2021043169A1 (zh) * 2019-09-02 2021-03-11 成都盛世君联生物技术有限公司 特异性结合b细胞成熟抗原的抗体及其用途
KR20220116221A (ko) * 2019-12-16 2022-08-22 난징 레전드 바이오테크 씨오., 엘티디. Bcma를 표적화하는 단일 도메인 항체 및 키메라 항원 수용체 및 이들의 사용 방법
PE20230464A1 (es) * 2020-06-30 2023-03-14 Teneobio Inc Union de anticuerpos multiespecificos a bcma
CN111848798B (zh) * 2020-07-27 2022-05-13 源道隆(苏州)医学科技有限公司 可结合bcma的纳米抗体及其应用
WO2022098771A1 (en) * 2020-11-03 2022-05-12 Ab Studio Inc. Multispecific antibodies and uses thereof
WO2022098787A1 (en) 2020-11-04 2022-05-12 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
EP4032910A1 (en) * 2021-01-22 2022-07-27 ETH Zurich Bispecific binding agent that binds to cd3 and a fluorophore
WO2022199555A1 (en) * 2021-03-23 2022-09-29 Guangzhou Lintonpharm Co., Ltd. A multispecific antigen binding protein binding to cd3 and the use thereof
KR20240052771A (ko) * 2021-09-08 2024-04-23 케이에스큐 세러퓨틱스 인코포레이티드 림프구 효력 검정
WO2023133357A2 (en) * 2022-01-10 2023-07-13 Expression Therapeutics, Llc Engineered t cells
CN119923411A (zh) * 2022-09-30 2025-05-02 诺纳生物(苏州)有限公司 靶向cd3的抗体及其用途
JP2025539364A (ja) * 2022-11-22 2025-12-05 エクスプレッション セラピューティクス, エルエルシー 遺伝子操作t細胞
EP4648854A1 (en) * 2023-01-10 2025-11-19 Expression Therapeutics, LLC Engineered t cells
CA3205511A1 (en) * 2023-04-19 2025-03-17 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
CN118994391A (zh) * 2023-05-16 2024-11-22 亘喜生物科技(上海)有限公司 特异性结合cd38的抗体及其制法和应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP2000515002A (ja) 1996-06-27 2000-11-14 フラームス・インテルウニフェルジテール・インスティテュート・フォール・ビオテヒノロジー・ヴェーゼットウェー 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
AU2291700A (en) 1999-01-19 2000-08-07 Unilever Plc Method for producing antibody fragments
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
CA2457636C (en) 2001-08-10 2012-01-03 Aberdeen University Antigen binding domains
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
DK1629011T3 (da) 2003-05-31 2010-05-03 Micromet Ag Humane anti-humane-DC3-bindingsmolekyler
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
ES2393555T3 (es) 2003-10-22 2012-12-26 Keck Graduate Institute Métodos para la síntesis de polipéptidos hetero-multiméricos en levaduras usando una estrategia de apareamiento haploide.
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ (ミュンヘン) ゲーエムベーハー 交差種特異的(cross−species−specific)抗体を含む組成物および該組成物の使用
SG169348A1 (en) 2006-01-25 2011-03-30 Univ Erasmus Medical Ct Generation of heavy-chain only antibodies in transgenic animals
CN101490085A (zh) * 2006-06-12 2009-07-22 特鲁比昂药品公司 具有效应功能的单链多价结合蛋白
SG10201808730VA (en) 2007-04-03 2018-11-29 Amgen Res Munich Gmbh Cross-species-specific binding domain
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
KR101589785B1 (ko) 2009-03-10 2016-01-28 바이오젠 엠에이 인코포레이티드 항-bcma 항체
JP5593641B2 (ja) 2009-06-26 2014-09-24 味の素株式会社 減塩飲食品用組成物
DK2509409T3 (en) 2009-12-10 2016-11-14 Regeneron Pharma MICE, WHICH PRODUCES HEAVY CHAIN ANTIBODIES
US20130273055A1 (en) * 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
ES3065694T3 (en) 2012-04-11 2026-05-07 Us Health Chimeric antigen receptors targeting b-cell maturation antigen
SG10202006507XA (en) 2012-05-30 2020-08-28 Chugai Pharmaceutical Co Ltd Target-tissue-specific antigen-binding molecule
US10968276B2 (en) * 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
CN106255410B (zh) 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
JP6775422B2 (ja) * 2014-03-28 2020-10-28 ゼンコー・インコーポレイテッドXencor、 Inc. Cd38及びcd3に結合する二重特異性抗体
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
JP2017536830A (ja) * 2014-11-26 2017-12-14 ゼンコー・インコーポレイテッドXencor、 Inc. Cd3及びcd38に結合するヘテロ二量体抗体
EP3029068A1 (en) * 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
US11046767B2 (en) 2015-05-13 2021-06-29 Ablynx N.V. T cell recruiting polypeptides based on CD3 reactivity
AU2016293942B2 (en) 2015-07-10 2022-06-16 Merus B.V. Human CD3 binding antibody
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2017031104A1 (en) * 2015-08-17 2017-02-23 Janssen Pharmaceutica Nv Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
WO2017133175A1 (en) 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
KR102512934B1 (ko) 2016-08-10 2023-03-23 레전드 바이오테크 아일랜드 리미티드 Bcma를 표적으로 하는 키메라 항원 수용체 및 이들의 이용 방법
JP7685735B2 (ja) * 2016-12-02 2025-05-30 アンヘレス セラピューティクス インコーポレイテッド 合成免疫受容体およびその使用方法
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
CN113766919B (zh) * 2019-04-05 2025-09-16 2赛文缇生物公司 制造抗bcma car t细胞

Similar Documents

Publication Publication Date Title
JP2021508469A5 (enExample)
CN112969476B (zh) 多特异性蛋白分子
JP2012501670A5 (enExample)
JP2013545455A5 (enExample)
JP2019201643A5 (enExample)
JP2012501669A5 (enExample)
TW201837174A (zh) 抗gprc5d抗體及包含該抗體之分子
JP2017532952A5 (enExample)
JP2019513777A5 (enExample)
JP2020501531A5 (enExample)
JP2018502060A5 (enExample)
JP2017504578A5 (enExample)
JP2021510521A5 (enExample)
WO2020114478A1 (zh) Cd3抗体及其药物用途
JP2015163068A5 (enExample)
JP2013502913A5 (enExample)
JP2018521638A5 (enExample)
JP2018527919A5 (enExample)
JP2018522888A5 (enExample)
JP2017535257A5 (enExample)
JP2011509245A5 (enExample)
JP2016536322A5 (enExample)
JP2018507188A5 (enExample)
JP2023540526A5 (enExample)
JP2017504577A5 (enExample)